Literature DB >> 9661880

Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.

R J Vlietstra1, D C van Alewijk, K G Hermans, G J van Steenbrugge, J Trapman.   

Abstract

Loss of chromosome 10q is a frequently observed genetic defect in prostate cancer. Recently, the PTEN/MMAC1 tumor suppressor gene was identified and mapped to chromosome 10q23.3. We studied PTEN structure and expression in 4 in vitro cell lines and 11 in vivo xenografts derived from six primary and nine metastatic human prostate cancers. DNA samples were allelotyped for eight polymorphic markers within and surrounding the PTEN gene. Additionally, the nine PTEN exons were tested for deletions. In five samples (PC3, PC133, PCEW, PC295, and PC324), homozygous deletions of the PTEN gene or parts of the gene were detected. PC295 contained a small homozygous deletion encompassing PTEN exon 5. In two DNAs (PC82 and PC346), nonsense mutations were found, and in two (LNCaP and PC374), frame-shift mutations were found. Missense mutations were not detected. PTEN mRNA expression was clearly observed in all cell lines and xenografts without large homozygous deletions, showing that PTEN down-regulation is not an important mechanism of PTEN inactivation. The high frequency (60%) of PTEN mutations and deletions indicates a significant role of this tumor suppressor gene in the pathogenesis of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661880

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  108 in total

1.  Sortilin regulates progranulin action in castration-resistant prostate cancer cells.

Authors:  Ryuta Tanimoto; Alaide Morcavallo; Mario Terracciano; Shi-Qiong Xu; Manuela Stefanello; Simone Buraschi; Kuojung G Lu; Demetrius H Bagley; Leonard G Gomella; Katia Scotlandi; Antonino Belfiore; Renato V Iozzo; Andrea Morrione
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

2.  Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.

Authors:  Mahandranauth A Chetram; Valerie Odero-Marah; Cimona V Hinton
Journal:  Mol Cancer Res       Date:  2010-11-12       Impact factor: 5.852

3.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

4.  Transcriptional Regulation of EGR1 by EGF and the ERK Signaling Pathway in Prostate Cancer Cells.

Authors:  Jennifer Gregg; Gail Fraizer
Journal:  Genes Cancer       Date:  2011-09

5.  Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.

Authors:  Roberta Malaguarnera; Antonella Sacco; Alaide Morcavallo; Sebastiano Squatrito; Antimo Migliaccio; Andrea Morrione; Marcello Maggiolini; Antonino Belfiore
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

6.  Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death.

Authors:  Mathew J Edick; Lia Tesfay; Laura E Lamb; Beatrice S Knudsen; Cindy K Miranti
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

7.  Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling.

Authors:  Ase Bratland; Piet J Boender; Hanne K Høifødt; Ingrid H G Østensen; Rob Ruijtenbeek; Meng-Yu Wang; Jens P Berg; Wolfgang Lilleby; Øystein Fodstad; Anne Hansen Ree
Journal:  Clin Exp Metastasis       Date:  2009-03-18       Impact factor: 5.150

8.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 9.  Advancing precision medicine for prostate cancer through genomics.

Authors:  Sameek Roychowdhury; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

10.  HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells.

Authors:  Rusha Thomas; Myoung H Kim
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.